Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
CNS Oncol ; 12(3): CNS102, 2023 09 01.
Article in English | MEDLINE | ID: mdl-37462385

ABSTRACT

Aim: The EMulate Therapeutics Voyager™ is a simple, wearable, home-use device that uses an alternating electromagnetic field to alter biologic signaling within cells. Objective: To assess the safety/feasibility of the Voyager in the treatment of recurrent glioblastoma (rGBM). Methods: In this study, patients with rGBM were treated with Voyager as monotherapy or in combination with standard chemotherapy at the Investigator's discretion. Safety was assessed by incidence of adverse events associated with the Voyager. Patients were followed until death. Results: A total of 75 patients were enrolled and treated for at least one day with the Voyager (safety population). Device-related adverse events were uncommon and generally did not result in interruption or withdrawal from treatment. There were no serious adverse events associated with Voyager. A total of 60 patients were treated for at least one month (clinical utility population). The median progression-free survival (PFS) was 17 weeks (4.3 months) in the Voyager only group (n = 24) and 21 weeks (5.3 months) in the Voyager + concurrent therapy group (n = 36). The median overall survival (OS) was 7 months in the Voyager only group and 9 months in the Voyager + concurrent therapy group. In patients treated with Voyager + concurrent therapy, the median OS for patients enrolled with their 1st or 2nd recurrence (n = 26) was 10 months, while in patients enrolled with their 3rd or 4th recurrence (n = 10) OS was 7 months. Conclusion: The data support the safety and feasibility of the Voyager for the treatment of rGBM. Further prospective study of the device is warranted. Trial Registration Number: NCT02296580 (ClinicalTrials.gov).


Subject(s)
Brain Neoplasms , Glioblastoma , Humans , Brain Neoplasms/drug therapy , Feasibility Studies , Glioblastoma/drug therapy , Neoplasm Recurrence, Local , Prospective Studies
2.
Neurooncol Adv ; 5(Suppl 1): i49-i57, 2023 May.
Article in English | MEDLINE | ID: mdl-37287582

ABSTRACT

Meningiomas are the most common central nervous system tumors. Although these tumors are extra-axial, a relatively high proportion (10%-50%) of meningioma patients have seizures that can substantially impact the quality of life. Meningiomas are believed to cause seizures by inducing cortical hyperexcitability that results from mass effect and cortical irritation, brain invasion, or peritumoral brain edema. In general, meningiomas that are associated with seizures have aggressive features, with risk factors including atypical histology, brain invasion, and higher tumor grade. Somatic NF2 mutated meningiomas are associated with preoperative seizures, but the effect of the driver mutation is mediated through atypical features. While surgical resection is effective in controlling seizures in most patients with meningioma-related epilepsy, a history of seizures and uncontrolled seizures prior to surgery is the most significant predisposing factor for persistent postoperative seizures. Subtotal resection (STR) and relatively larger residual tumor volume are positive predictors of postoperative seizures. Other factors, including higher WHO grade, peritumoral brain edema, and brain invasion, are inconsistently associated with postoperative seizures, suggesting they might be crucial in the development of an epileptogenic focus, but do not appear to play a substantial role after seizure activity has been established. Herein, we review and summarize the current literature surrounding meningioma-related epilepsy and underscore the interaction of multiple factors that relate to seizures in patients with meningioma.

4.
J Neurooncol ; 155(3): 255-264, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34626296

ABSTRACT

OBJECTIVE: While adjuvant treatment regimens have been modified for older patients with glioblastoma (GBM), surgical strategies have not been tailored. METHODS: Clinical data of 48 consecutive patients aged 70 years or older, who underwent surgical resection for GBM with intraoperative ultrasonography (IoUS) alone or combination with intraoperative MRI (IoMRI) at Yale New Haven Hospital were retrospectively reviewed. Variables were analyzed, and comparative analyses were performed. RESULTS: The addition of IoMRI was not superior to IoUS alone in terms of overall survival (OS) (P = 0.306), Karnofsky Performance Score (KPS) at postoperative 6 weeks (P = 0.704) or extent of resection (P = 0.263). Length of surgery (LOSx), however, was significantly longer (P = 0.0002) in the IoMRI group. LOSx (P = 0.015) and hospital stay (P = 0.025) were predictors of postoperative complications. Increased EOR (GTR or NTR) (P = 0.030), postoperative adjuvant treatment (P < 0.0001) and postoperative complications (P = 0.006) were predictive for OS. Patients with relatively lower preoperative KPS scores (<70) showed significant improvement at postoperative 6 weeks (P<0.0001). Patients with complications (P = 0.038) were more likely to have lower KPS at postoperative 6 weeks. CONCLUSIONS: Aggressive management with surgical resection should be considered in older patients with GBM, even those with relatively poor KPS. The use of ioMRI in this population does not appear to confer any measurable benefit over ioUS in experienced hands, but prolongs the length of surgery significantly, which is a preventable prognostic factor for impeding care.


Subject(s)
Brain Neoplasms , Glioblastoma , Aged , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/mortality , Brain Neoplasms/surgery , Glioblastoma/diagnostic imaging , Glioblastoma/mortality , Glioblastoma/surgery , Humans , Karnofsky Performance Status , Neurosurgical Procedures , Postoperative Complications/epidemiology , Retrospective Studies , Treatment Outcome
5.
J Neurooncol ; 154(2): 237-246, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34350560

ABSTRACT

PURPOSE: As sphenoid wing meningiomas (SWMs) are associated with varying degrees of bony involvement, we sought to understand potential relationships between genomic subgroup and this feature. METHODS: Patients treated at Yale-New Haven Hospital for SWM were reviewed. Genomic subgroup was determined via whole exome sequencing, while the extent of bony involvement was radiographically classified as no bone invasion (Type I), hyperostosis only (Type II), tumor invasion only (Type III), or both hyperostosis and tumor invasion (Type IV). Among additional clinical variables collected, a subset of tumors was identified as spheno-orbital meningiomas (SOMs). Machine-learning approaches were used to predict genomic subgroups based on pre-operative clinical features. RESULTS: Among 64 SWMs, 53% had Type-II, 9% had Type-III, and 14% had Type-IV bone involvement; nine SOMs were identified. Tumors with invasion (i.e., Type III or IV) were more likely to be WHO grade II (p: 0.028). Additionally, tumors with invasion were nearly 30 times more likely to harbor NF2 mutations (OR 27.6; p: 0.004), while hyperostosis only were over 4 times more likely to have a TRAF7 mutation (OR 4.5; p: 0.023). SOMs were a significant predictor of underlying TRAF7 mutation (OR 10.21; p: 0.004). CONCLUSIONS: SWMs with invasion into bone tend to be higher grade and are more likely to be NF2 mutated, while SOMs and those with hyperostosis are associated with TRAF7 variants. Pre-operative prediction of molecular subtypes based on radiographic bony characteristics may have significant biological and clinical implications based on known recurrence patterns associated with genomic drivers and grade.


Subject(s)
Hyperostosis , Meningeal Neoplasms , Meningioma , Genomics , Humans , Hyperostosis/diagnostic imaging , Hyperostosis/genetics , Meningeal Neoplasms/diagnostic imaging , Meningeal Neoplasms/genetics , Meningioma/diagnostic imaging , Meningioma/genetics , Treatment Outcome
6.
NPJ Precis Oncol ; 5(1): 8, 2021 Feb 12.
Article in English | MEDLINE | ID: mdl-33580181

ABSTRACT

Gliosarcoma is a variant of glioblastoma with equally poor prognosis and characterized by mixed glial and mesenchymal pathology. Metastasis is not uncommon but the involvement of the spinal cord is rare, and comprehensive genetic characterization of spinal gliosarcoma is lacking. We describe a patient initially diagnosed with a low-grade brain glioma via biopsy, followed by adjuvant radiation and temozolomide treatment. Nearly 2 years after diagnosis, she developed neurological deficits from an intradural, extramedullary tumor anterior to the spinal cord at T4, which was resected and diagnosed as gliosarcoma. Whole-exome sequencing (WES) of this tumor revealed a hypermutated phenotype, characterized by somatic mutations in key DNA mismatch repair (MMR) pathway genes, an abundance of C>T transitions within the identified somatic single nucleotide variations, and microsatellite stability, together consistent with temozolomide-mediated hypermutagenesis. This is the first report of a hypermutator phenotype in gliosarcoma, which may represent a novel genomic mechanism of progression from lower grade glioma.

7.
J Neurosurg ; 135(3): 835-844, 2020 Dec 04.
Article in English | MEDLINE | ID: mdl-33276341

ABSTRACT

OBJECTIVE: The association of seizures with meningiomas is poorly understood. Moreover, any relationship between seizures and the underlying meningioma genomic subgroup has not been studied. Herein, the authors report on their experience with identifying clinical and genomic factors associated with preoperative and postoperative seizure presentation in meningioma patients. METHODS: Clinical and genomic sequencing data on 394 patients surgically treated for meningioma at Yale New Haven Hospital were reviewed. Correlations between clinical, histological, or genomic variables and the occurrence of preoperative and postoperative seizures were analyzed. Logistic regression models were developed for assessing multiple risk factors for pre- and postoperative seizures. Mediation analyses were also conducted to investigate the causal pathways between genomic subgroups and seizures. RESULTS: Seventeen percent of the cohort had presented with preoperative seizures. In a univariate analysis, patients with preoperative seizures were more likely to have tumors with a somatic NF2 mutation (p = 0.020), WHO grade II or III tumor (p = 0.029), atypical histology (p = 0.004), edema (p < 0.001), brain invasion (p = 0.009), and worse progression-free survival (HR 2.68, 95% CI 1.30-5.50). In a multivariate analysis, edema (OR 3.11, 95% CI 1.46-6.65, p = 0.003) and atypical histology (OR 2.00, 95% CI 1.03-3.90, p = 0.041) were positive predictors of preoperative seizures, while genomic subgroup was not, such that the effect of an NF2 mutation was indirectly mediated through atypical histology and edema (p = 0.012). Seizure freedom was achieved in 83.3% of the cohort, and only 20.8% of the seizure-free patients, who were more likely to have undergone gross-total resection (p = 0.031), were able to discontinue antiepileptic drug use postoperatively. Preoperative seizures (OR 3.54, 95% CI 1.37-9.12, p = 0.009), recurrent tumors (OR 2.89, 95% CI 1.08-7.74, p = 0.035), and tumors requiring postoperative radiation (OR 2.82, 95% CI 1.09-7.33, p = 0.033) were significant predictors of postoperative seizures in a multivariate analysis. CONCLUSIONS: Seizures are relatively common at meningioma presentation. While NF2-mutated tumors are significantly associated with preoperative seizures, the association appears to be mediated through edema and atypical histology. Patients who undergo radiation and/or have a recurrence are at risk for postoperative seizures, regardless of the extent of resection. Preoperative seizures may indeed portend a more potentially aggressive molecular entity and challenging clinical course with a higher risk of recurrence.

8.
BMC Cancer ; 16(1): 842, 2016 11 04.
Article in English | MEDLINE | ID: mdl-27809808

ABSTRACT

BACKGROUND: Gliomas are the most common primary brain tumors in adults and invariably carry a poor prognosis. Recent clinical studies have demonstrated the safety and compelling survival benefit when tumor treating fields (TTFields) are added to temozolomide for patients with newly diagnosed glioblastoma. TTFields are low-intensity, intermediate frequency (200 kHz) alternating electric fields, delivered directly to a patient's brain through the local application of non-invasive transducer arrays. Experimental simulations have demonstrated that TTFields distribute in a non-uniform manner within the brain. To ensure patients receive the maximal therapeutic level of TTFields at the site of their tumor, tumor burden is mapped and an optimal array layout is personalized using the NovoTAL software. The NovoTAL software utilizes magnetic resonance imaging (MRI) measurements for head size and tumor location obtained from axial and coronal T1 postcontrast sequences to determine the optimal paired transducer array configuration that will deliver the maximal field intensity at the site of the tumor. In clinical practice, physicians planning treatment with TTFields may determine that disease activity is more accurately represented in noncontrast-enhancing sequences. Here we present and discuss a series of 8 cases where a treating physician has utilized non-contrast enhancement and advanced imaging to inform TTFields treatment planning based on a clinical evaluation of where a patient is believed to have active tumor. This case series is, to our knowledge, the first report of this kind in the literature. CASE PRESENTATIONS: All patients presented with gliomas (grades 2-4) and ranged in age from 49 to 65 years; 5 were male and 3, female. Each patient had previously received standard therapy including surgery, radiation therapy and/or chemotherapy prior to initiation of TTFields. The majority had progressed on prior therapy. A standard pre- and postcontrast MRI scan was acquired and used for TTFields treatment planning. CONCLUSION: This paper details important approaches for integrating clinical considerations, nonmeasurable disease and advanced imaging into the treatment planning workflow for TTFields. As TTFields become integrated into standard care pathways for glioblastoma, this case series demonstrates that treatment planning beyond the extent of contrast enhancement is clinically feasible and should be prospectively compared to standard treatment planning in a clinical trial setting, in order to determine the impact on patient outcomes.


Subject(s)
Antineoplastic Agents/administration & dosage , Dacarbazine/analogs & derivatives , Glioma/diagnostic imaging , Glioma/drug therapy , Image Enhancement , Magnetic Resonance Imaging , Aged , Brain/pathology , Combined Modality Therapy , Dacarbazine/administration & dosage , Female , Glioma/pathology , Humans , Male , Middle Aged , Neoplasm Grading , Temozolomide , Treatment Outcome
9.
Neurol Clin Pract ; 4(1): 26-33, 2014 Feb.
Article in English | MEDLINE | ID: mdl-29473588

ABSTRACT

Hypothermia, defined as a core temperature below 35°C, can occur in a variety of clinical settings, including environmental exposure, shock, infection, metabolic disorders (such as hypothyroidism, adrenal insufficiency, and Wernicke encephalopathy), malnutrition, and alcohol or drug toxicity. Typically, hypothermia should resolve with treatment of the underlying disorder. However, in rare cases patients experience recurrent episodes of hypothermia in the context of a stereotyped syndrome due to a hypothalamic lesion, which can be either congenital or acquired. The episodes are characterized by progressive confusion and a decreased level of arousal, hypothermia, and eventual resolution with a return to baseline. Additional clinical findings during episodes may include diaphoresis, asterixis, bradycardia, and thrombocytopenia. These recurrent episodes represent periodic hypothermia.

10.
Hematol Oncol Clin North Am ; 26(4): 811-23, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22794285

ABSTRACT

The optimal treatment of anaplastic gliomas is controversial. Options for treatment include radiation, chemotherapy or a combination of modalities. This article describes how treatment algorithms for anaplastic gliomas have evolved and interprets the results of recent studies. The available evidence indicates that patients can be treated with either chemotherapy or radiation as initial therapy, with use of the other treatment modality at relapse. Whether subpopulations exist for whom one treatment modality is superior to the other at initial diagnosis must be studied prospectively.


Subject(s)
Brain Neoplasms/therapy , Glioma/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Neoplasms/drug therapy , Brain Neoplasms/radiotherapy , Combined Modality Therapy , Glioma/drug therapy , Glioma/radiotherapy , Humans , Neoplasm Grading
11.
Neurocrit Care ; 17(2): 268-70, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22528275

ABSTRACT

BACKGROUND: Plantar flexion with plantar stimulation has been well described in brain death, and is compatible with brain death. However, plantar flexion with stimulation to the dorsal surface of the foot has not been reported previously in brain dead patients. METHODS: Case report with Technetium-99 m hexamethylpropyleneamine oxime brain scan and video. RESULTS: A 46-year-old woman suffered severe anoxic brain injury following massive pulmonary embolism 5 days after arthroscopic knee surgery. Neurologic examination was consistent with brain death, with the exception of plantar flexion when noxious stimulation was applied to the dorsal surface of the great toe on each side. Ancillary testing with a technetium-99 m nuclear scan demonstrated absence of cerebral perfusion, supporting the diagnosis of brain death. CONCLUSIONS: Noxious stimulation to the dorsal surface of the foot may trigger spinally mediated plantar flexion in patients with brain death.


Subject(s)
Brain Death/diagnosis , Foot , Reflex , Spinal Cord , Brain Death/diagnostic imaging , Female , Humans , Hypoxia, Brain/diagnostic imaging , Hypoxia, Brain/etiology , Middle Aged , Perfusion Imaging , Pulmonary Embolism/complications , Radiopharmaceuticals , Technetium
12.
Arch Neurol ; 68(12): 1591-4, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22159058

ABSTRACT

OBJECTIVE: To compare the features of paraneoplastic syndrome of inappropriate antidiuretic hormone with those of limbic encephalitis. DESIGN: Case study. SETTING: Academic medical center. PATIENT: A 46-year-old woman with progressive memory impairment, hyponatremia, and seizures. INTERVENTIONS: Magnetic resonance imaging of the brain, fluoro-2-deoxyglucose positron emission tomography of the body, and immunohistochemical analysis of a resected tumor. RESULTS: Though the patient presented with clinical features of classic limbic encephalitis, magnetic resonance imaging, electroencephalogram, and cerebrospinal fluid analysis findings were unremarkable. Her chronic hyponatremia was ultimately found to be due to ectopic secretion of antidiuretic hormone by a neuroendocrine tumor with Merkel cell carcinoma phenotype. CONCLUSIONS: Patients presenting with memory impairment, seizures, and hyponatremia should undergo a thorough workup for occult malignancy. In addition to considering classic immune-mediated paraneoplastic limbic encephalitis, the ectopic secretion of antidiuretic hormone should be included in the differential diagnosis.


Subject(s)
Brain Neoplasms/complications , Endocrine Gland Neoplasms/complications , Inappropriate ADH Syndrome/complications , Inappropriate ADH Syndrome/diagnosis , Limbic Encephalitis/diagnosis , Brain Neoplasms/pathology , Carcinoma, Merkel Cell/complications , Carcinoma, Merkel Cell/pathology , Diagnosis, Differential , Endocrine Gland Neoplasms/diagnosis , Female , Humans , Memory Disorders/physiopathology , Middle Aged
14.
Neurologist ; 17(5): 241-8, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21881465

ABSTRACT

BACKGROUND: Therapeutic hypothermia is now commonly used to improve neurologic outcomes in eligible patients after cardiac arrest. The physiologic effects of cooling and pharmacologic effects of sedatives and neuromuscular blocking agents can affect the clinical exam and neurophysiologic findings. This can lead to uncertainty in neurologic prognostication. In this article, we review data on assessing prognosis in patients treated with therapeutic hypothermia. REVIEW SUMMARY: Features of the clinical examination, neurophysiologic testing (including somatosensory-evoked potentials and electroencephalography), serum/cerebrospinal fluid biomarkers and neuroimaging can be used to help predict prognosis. However, no single test can predict poor prognosis with absolute certainty. Given the features that help to predict poor, indeterminate, or good outcome, we provide practical advice in assessing neurologic prognosis after cardiac arrest in patients treated with therapeutic hypothermia. CONCLUSIONS: The American Academy of Neurology practice parameters for assessing prognosis after cardiac arrest may not be accurate for patients treated with therapeutic hypothermia. Application of these guidelines may lead to overly pessimistic prognostication and premature withdrawal of care. If uncertainty exists regarding the prognosis in a given patient after cardiac arrest, additional time should be allowed to pass, as patients may ultimately recover with good neurologic outcome.


Subject(s)
Heart Arrest/physiopathology , Heart Arrest/therapy , Hypothermia, Induced/methods , Outcome Assessment, Health Care , Electroencephalography , Evoked Potentials, Somatosensory , Humans , Neuroimaging , Neurologic Examination , Predictive Value of Tests , Prognosis
16.
J Stroke Cerebrovasc Dis ; 19(4): 269-72, 2010.
Article in English | MEDLINE | ID: mdl-20471856

ABSTRACT

BACKGROUND: Recent evidence has suggested that patients with right hemispheric stroke (RHS) present later to an emergency department, have a lower chance to receive intravenous (IV) recombinant tissue plasminogen activator (t-PA), and have poorer clinical outcomes than do patients with left hemispheric stroke (LHS). METHODS: We analyzed the rate of IV t-PA administration with respect to the side of the affected hemisphere in a large community population, to determine whether a difference exists. The study population was a large prospective cohort of patients with acute stroke treated with IV t-PA at our hospital's stroke center (October 2000 to October 2006). RESULTS: Of 2,932 patients presenting with ischemic stroke, 953 met criteria for study inclusion. In all, 151 patients received IV t-PA. Between groups, there was no significant difference in presentation within 3 hours after acute stroke (P=.180). There was no difference in the use of IV t-PA between patients with RHS and LHS (P=.237). CONCLUSIONS: There was no difference with respect to affected hemisphere in time to presentation to the emergency department. Furthermore, there was no difference in the rate of IV t-PA administration for patients with RHS versus LHS. This finding is in contrast to previous research on IV t-PA use in hemispheric stroke and may reflect improved recognition of right hemispheric syndromes.


Subject(s)
Functional Laterality , Stroke/drug therapy , Thrombolytic Therapy/statistics & numerical data , Tissue Plasminogen Activator/administration & dosage , Databases, Factual , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/therapeutic use , Humans , Logistic Models , Prospective Studies , Time Factors , Tissue Plasminogen Activator/therapeutic use , Treatment Outcome
18.
BMC Neurosci ; 7 Suppl 1: S3, 2006 Oct 30.
Article in English | MEDLINE | ID: mdl-17118157

ABSTRACT

Many cell biological pathways exhibit overall polarity (net movement of molecules in one direction) even though individual molecular interactions in the pathway are freely reversible. The A2 RNA trafficking pathway exhibits polarity in moving specific RNA molecules from the nucleus to localization sites in the myelin compartment of oligodendrocytes or dendritic spines in neurons. The A2 pathway is mediated by a ubiquitously expressed trans-acting trafficking factor (hnRNP A2) that interacts with a specific 11 nucleotide cis-acting trafficking sequence termed the A2 response element (A2RE) found in several localized RNAs. Five different molecular partners for hnRNP A2 have been identified in the A2 pathway: hnRNP A2 itself, transportin, A2RE RNA, TOG (tumor overexpressed gene) and hnRNP E1, each playing a key role in one particular step of the A2 pathway. Sequential interactions of hnRNP A2 with different molecular partners at each step mediate directed movement of trafficking intermediates along the pathway. Specific "rules of engagement" (both and, either or, only if) govern sequential interactions of hnRNP A2 with each of its molecular partners. Rules of engagement are defined experimentally using three component binding assays to measure differential binding of hnRNP A2 to one partner in the presence of each of the other partners in the pathway. Here we describe rules of engagement for hnRNP A2 binding to each of its molecular partners and discuss how these rules of engagement promote polarity in the A2 RNA trafficking pathway. For molecules with multiple binding partners, specific rules of engagement govern different molecular interactions. Rules of engagement are ultimately determined by structural relationships between binding sites on individual molecules. In the A2 RNA trafficking pathway rules of engagement governing interactions of hnRNP A2 with different binding partners provide the basis for polarity of movement of intermediates along the pathway.


Subject(s)
Cell Polarity/physiology , RNA/metabolism , Animals , Binding Sites , Biological Transport/physiology , Cell Nucleus/metabolism , Heterogeneous-Nuclear Ribonucleoprotein Group A-B/genetics , Heterogeneous-Nuclear Ribonucleoprotein Group A-B/metabolism , Karyopherins/metabolism , Protein Binding
SELECTION OF CITATIONS
SEARCH DETAIL
...